AGTX · XBRL financial data
Agentix financial statements, every fiscal year
The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (AGTX's year ends in late March)
| In thousands of dollars | Aug 31, 2021 | Mar 31, 2022 | Mar 31, 2023 | †Mar 31, 2024 | †Mar 31, 2025 | Mar 31, 2026 |
|---|---|---|---|---|---|---|
| Revenue | 1 | 1 | 0 | — | — | — |
| Cost of goods and services sold | 1 | 1 | 0 | — | — | — |
| Gross profit | 1 | 1 | 0 | — | — | — |
| Research and development | 365 | 280 | 712 | 175 | 181 | 125 |
| General and administrative | 66 | 165 | 140 | 347 | 70 | 68 |
| Total operating expenses | 1,341 | 2,627 | 1,372 | 745 | 513 | 445 |
| Operating income (loss) | (1,341) | (2,627) | (1,372) | (745) | (513) | (445) |
| Interest expense | — | — | 2 | 21 | 43 | 80 |
| Other income (expense) | (0) | — | 2 | (160) | (54) | — |
| Income tax expense (benefit) | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income (loss) | (1,340) | (2,627) | (1,374) | (585) | (567) | (486) |
| Earnings per share, diluted USD per share | — | — | — | (0.01) | (0.01) | (0.01) |
| Weighted average shares, diluted thousands of shares | — | — | — | 40,067 | 40,067 | 40,067 |
- † Share count changed about 1/4 in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 4x in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (AGTX's year ends in late March)
| In thousands of dollars | Aug 31, 2021 | Mar 31, 2022 | Mar 31, 2023 | †Mar 31, 2024 | †Mar 31, 2025 | Mar 31, 2026 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 2 | 0 | 12 | 7 | 4 | 1 |
| Inventory | 49 | 0 | — | — | — | — |
| Prepaid and other current assets | — | 16 | 249 | 100 | 96 | 0 |
| Total current assets | 51 | 16 | 261 | 106 | 100 | 1 |
| Total assets | 51 | 16 | 261 | 106 | 100 | 1 |
| Accounts payable | 121 | 145 | 1,057 | 962 | 969 | 716 |
| Accrued liabilities | 0 | 0 | 9 | 24 | 60 | 144 |
| Total current liabilities | 607 | 1,093 | 2,511 | 2,667 | 3,205 | 3,596 |
| Total liabilities | 607 | 1,093 | 2,511 | 2,667 | 3,205 | 3,596 |
| Accumulated deficit | (1,704) | (3,996) | (5,369) | (5,954) | (6,522) | (7,007) |
| Total stockholders' equity | (556) | (1,077) | (2,249) | (2,560) | (3,104) | (3,596) |
| Total liabilities and equity | 51 | 16 | 261 | 106 | 100 | 1 |
| Common shares outstanding (cover page) thousands of shares | 34,875 | 38,917 | 40,067 | 10,067 | 40,067 | 40,067 |
- † Share count changed about 1/4 in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 4x in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (AGTX's year ends in late March)
| In thousands of dollars | Aug 31, 2021 | Mar 31, 2022 | Mar 31, 2023 | †Mar 31, 2024 | †Mar 31, 2025 | Mar 31, 2026 |
|---|---|---|---|---|---|---|
| Net income (loss) | (1,340) | (2,627) | (1,374) | (585) | (567) | (486) |
| Net cash from operating activities | (421) | (25) | (89) | (110) | (125) | (109) |
| Net cash from investing activities | 0 | 0 | 0 | 0 | 0 | 0 |
| Proceeds from issuing common stock | 180 | 0 | 50 | 0 | — | — |
| Net cash from financing activities | 180 | 0 | 100 | 93 | 100 | 110 |
| Net change in cash | (241) | (25) | 12 | (6) | (2) | (4) |
- † Share count changed about 1/4 in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 4x in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Agentix | 0 | not reported | (26) | 40.1M | 0.0 quarters | 10-QJun 30, 2026 |
| Evofem Biosciences | 285 | 2,633 | (3,140)* | 132.5M | 0.1 quarters | 10-QJun 30, 2026 |
| Galera Therapeutics | 5,500 | not reported | (875) | 160.4M | 6.3 quarters | 10-QMar 31, 2026 |
| ProtoKinetix | 1.1 | not reported | 0.6* | 411.6M | — | 10-KDec 31, 2025 |
| Regen BioPharma | 0.2 | 59 | (24)* | 1.7B | 0.0 quarters | 10-QJun 30, 2026 |
| Twinlab Consolidated Holdings | 13 | not reported | (907)* | 259.1M | 0.0 quarters | 10-KDec 31, 2024 |
| Decoy Therapeutics | 8,289 | 228 | (2,652)* | 655,185 | 3.1 quarters | 10-QJun 30, 2026 |
| Hepion Pharmaceuticals | 1,629 | not reported | (1,394)* | 90.2M | 1.2 quarters | 10-QJun 30, 2026 |
| Nomad Power Solutions | 12,670 | not reported | (1,612)* | 16.1M | 7.9 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.